Insider Trading November 20, 2026 02:46 AM

Acrivon CEO Offloads $2,581 in Shares to Cover Tax Bill

Peter Blume-Jensen's sale of 1,780 shares was tied to restricted stock unit vesting, with the stock trading near its 52-week low.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ACRV

Acrivon Therapeutics CEO Peter Blume-Jensen sold 1,780 shares for $2,581 on November 17, 2026, at a weighted average price of $1.45, to satisfy tax withholding obligations on vesting restricted stock units. The transaction included 1,276 shares disposed directly by Blume-Jensen and 504 shares indirectly by his spouse, co-founder and EVP Kristina Masson. Following the sale, Blume-Jensen directly holds 2,228,776 shares and Masson indirectly holds 385,355 shares. Acrivon's stock, trading at $1.40, is down 42% year-to-date and near its 52-week low of $1.27. The filing was signed by attorney-in-fact Adam D. Levy on November 19, 2026. Separately, Jefferies reiterated a Buy rating with a $14 price target.

Acrivon CEO Offloads $2,581 in Shares to Cover Tax Bill
ACRV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Peter Blume-Jensen sold 1,780 shares for $2,581 to cover tax withholding on vesting RSUs, a non-discretionary transaction.
  • The sale comes as Acrivon's stock trades near its 52-week low of $1.27, down 42% year-to-date.
  • Jefferies reiterated a Buy rating with a $14 price target, citing confidence in management and the development of ACR-525.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) disclosed that its President and Chief Executive Officer, Peter Blume-Jensen, sold common stock valued at $2,581 on November 17, 2026. The transaction involved 1,780 shares at a price of $1.45 per share.

The sale was executed to meet mandatory tax withholding requirements triggered by the vesting of restricted stock units. Of the total, Dr. Blume-Jensen directly disposed of 1,276 shares. An additional 504 shares were indirectly disposed of by Dr. Kristina Masson, co-founder and Executive Vice President of Acrivon Therapeutics and Dr. Blume-Jensen's spouse.

The reported price of $1.45 represents the weighted average price of 4,070 shares sold by a broker on the same date to cover withholding tax liabilities for a group of the Issuer's employees, with proceeds allocated pro rata.

The transaction comes as Acrivon's stock trades at $1.40, down 42% year-to-date and near its 52-week low of $1.27. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value of $1.84, making it one to watch on the platform's most undervalued stocks list.

Following these transactions, Dr. Blume-Jensen directly holds 2,228,776 shares of Acrivon Therapeutics common stock. Dr. Masson indirectly holds 385,355 shares. Dr. Masson disclaims beneficial ownership of the directly held securities by Dr. Blume-Jensen except to the extent of her pecuniary interest, and Dr. Blume-Jensen disclaims beneficial ownership of the indirectly held securities by Dr. Masson except to the extent of his pecuniary interest.

The filing was signed by Adam D. Levy, acting as Attorney-in-Fact for both Dr. Blume-Jensen and Dr. Masson, on November 19, 2026.

In other recent news, Jefferies has reiterated its Buy rating for Acrivon Therapeutics, maintaining a price target of $14.00. This decision follows an inflammation and immunology key opinion leader event that provided insights into the company's drug development path. Jefferies expressed increased confidence in Acrivon's management and the rationale for the development of ACR-525. The firm noted that the event and subsequent management discussions have positively influenced their outlook on the company. These recent developments highlight the ongoing advancements in Acrivon's therapeutic projects.

For deeper insights into Acrivon's financial health and future prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.

Risks

  • The stock is down 42% year-to-date and near its 52-week low, indicating negative market sentiment and potential further volatility.
  • The insider sale, while for tax purposes, could be perceived negatively by investors, adding downward pressure on the share price.
  • The wide gap between the analyst price target of $14.00 and the current price of $1.40 suggests significant uncertainty about the company's prospects.

More from Insider Trading

PPL Finance Chief Henninger Offloads $87,475 in Stock Under Pre-Set Trading Plan Nov 20, 2026 PayPal Global Markets President Offloads $241K in Shares Under Pre-Arranged Plan Nov 20, 2026 Braze Accounting Chief Offloads $100K in Shares Under Sell-to-Cover Plan Nov 20, 2026 Zomedica Director Powers Adds 175,000 Shares as Stock Slips Nov 20, 2026 WEX Director Lauren Taylor Wolfe Offloads $2.9 Million in Stock Nov 20, 2026